Strong growth from Vyepti[®] and focused commercial execution drive total revenue growth of +16% CER (+13% CER underlying) in H1 2026

Lundbeck reported first-half 2026 revenue of DKK 13,588 million, up +16% CER (+11% DKK), driven by double-digit growth in the U.S. and Europe and commercial momentum from Vyepti and Rexulti. Reported performance also reflected a transition to a partnership model across 27 markets; after adjusting for a planned one-time DKK 470 million inventory build in Q1 2026, underlying revenue increased +13% CER.

Analysis

The key issue is not the reported growth rate; it is whether this is true end-demand or a channel/partner accounting effect. A one-time inventory build can flatter the top line for a quarter or two, but it usually leaves a weaker setup for the next compare if partners normalize stock. That makes the next 1-2 quarters more important than the current print for any valuation re-rating.

Strategically, the partnership model is a capital-light lever: it should improve ROIC and reduce local commercial burn, but it also cedes some control over pricing, promotion, and launch cadence to third parties. That tends to help cash conversion before it helps durable multiple expansion. The second-order winner may be the partner network itself; the second-order loser is not just Lundbeck’s direct competitors, but also any small-market branded pharma name that depends on heavy in-house sales infrastructure.

The contrarian view is that the market may be too focused on the headline acceleration and too little on product concentration and durability. If the growth is being driven by a narrow set of assets, the burden of proof shifts to margin expansion and FCF, not revenue. Falsifiers are simple: a 3Q slowdown into high-single-digits or lower, evidence of partner destocking, or any guidance that implies the current run-rate is not self-sustaining over 6-18 months.

Key Decisions for Investors

• Do not chase the print in LUN.CO; wait for Q3 sell-through and cash conversion. Better entry is a 3-5% post-earnings pullback after the market digests the inventory distortion.
• Set a hard alert on 3Q organic growth and operating margin: if organic growth drops below high-single-digits CER or margin fails to expand despite the partnership model, fade rallies in LUN.CO.
• If you have access to European single-name or basket shorts, consider a relative-value long LUN.CO / short broad European pharma exposure only if management confirms the partnership model is driving FCF leverage; the trade dies if inventory unwind shows up in 2H.
• Watch competitor script data in migraine and psychiatry over the next 1-3 months. If peers like ABBV or AMGN show accelerating share, treat this as a temporary channel effect rather than a durable share-gain story.